Ceribell Wins $2,171 NTAP for Delirium Monitor, Expanding ICU Coverage
Event summary
- Ceribell secured a New Technology Add-on Payment (NTAP) from CMS for its Delirium Monitor System, effective October 1, 2026.
- The NTAP provides up to $2,171 per eligible Medicare patient case using the system.
- This follows FDA 510(k) clearance in December 2025, making it the first and only FDA-cleared device for delirium screening.
- The system integrates seizure and delirium monitoring into a single point-of-care EEG platform.
The big picture
Ceribell's NTAP approval represents a strategic validation of continuous EEG monitoring as a critical tool in ICU settings. The payment mechanism addresses longstanding reimbursement challenges for novel neurological technologies, potentially setting a precedent for other point-of-care diagnostics. With this clearance, Ceribell positions itself as the sole provider of FDA-cleared solutions for both seizure and delirium monitoring, creating a differentiated offering in the acute care market.
What we're watching
- Adoption Pace
- How quickly hospitals will integrate the Delirium Monitor System into standard ICU protocols.
- Reimbursement Impact
- Whether the NTAP payment structure will drive broader Medicare and private insurer coverage.
- Competitive Response
- How existing EEG providers may react to Ceribell's expanded platform capabilities.